At the 2025
European Alliance of Associations for Rheumatology (EULAR), one of the most powerful sessions focused on a group of patients who often feel overlooked in research and care: people living with difficult-to-treat and poly-refractory rheumatoid arthritis (RA). In this Debrief from our
Go With Us program, Deb Constien walked through real case studies and emerging treatment strategies that offer both clarity and cautious hope.
This topic matters deeply because for many people with RA, treatment does not follow a straight line. Medications fail. Symptoms persist. Decisions become harder. This session helped explain why that happens and what new paths may be opening.
What does “difficult-to-treat” actually mean?
Researchers estimate that
about 5 to 20 percent of people with RA fall into the difficult-to-treat category. Within that group,
roughly 3 percent are considered
poly-refractory, meaning they have failed multiple medications across different drug classes, often more than once.
An important and validating takeaway is this:
Less than
60 percent of people with difficult-to-treat RA show clear inflammation on imaging like ultrasound or MRI.
That means pain, fatigue, and disability can still be very real even when scans do not show dramatic inflammation. This helps explain why some patients feel dismissed or misunderstood when tests do not line up with lived experience.
Case study spotlight: When standard treatments are no longer enough
One of the most striking moments in the session was a real-world case of a
25-year-old woman with severe, poly-refractory RA.
Key features of her case included:
- Extremely high and unstable CRP levels that never normalized
- Widespread joint destruction seen on imaging
- Failure of every standard RA treatment option
- Meeting
8 EULAR criteria for difficult-to-treat RA, far beyond the minimum needed
The clinical question became clear:
Why is this disease so resistant to treatment, and what options are left?
CAR-T cell therapy: High risk, high impact
Because all standard therapies had failed, clinicians pursued
CAR-T cell therapy, a treatment more commonly associated with cancer care but now being explored in severe autoimmune disease.
This treatment is not simple or gentle. The patient experienced two serious complications:
- Cytokine Release Syndrome (CRS), where the immune system becomes dangerously overactivated
- Neurotoxicity, along with a serious infection
She required
about two months of hospitalization to stabilize.
But one year later, the outcome was remarkable:
- CRP levels returned to normal
- No active joint inflammation on disease activity scoring
- No biologics, no DMARDs, and no steroids
- Sustained remission
This does not mean CAR-T is ready for widespread use in RA. But it does represent a powerful proof of concept that immune “resetting” may be possible.
Beyond medications: Neural modulation as a new frontier
The session also explored
non-drug approaches aimed at calming immune activity by working through the nervous system. This area of research is expanding quickly and may become especially important for difficult-to-treat RA.
Some approaches discussed included:
- Implanted vagus nerve stimulation
A very small device is surgically placed on the vagus nerve and activated with a magnet for about one minute per day. Long-term follow-up showed CRP levels moving toward normal and disease activity stabilizing over time. - Splenic nerve stimulation
This targets communication between the spleen and immune system, helping reduce inflammatory signaling throughout the body. - Non-invasive cervical vagus nerve stimulation
An external device placed on the neck that stimulates the vagus nerve without surgery. Early trials suggest improvements in pain and disease activity. - Auricular (ear-based) stimulation
Devices that stimulate nerve pathways through the ear are also being studied as another non-invasive option.
Researchers often describe these approaches as ways of “resetting” immune signaling rather than suppressing it with medication alone.
Key takeaways for patients
If you are living with difficult-to-treat RA, this session offered several important reminders:
- Not responding to treatment is not a personal failure and not always visible on scans
- A small subset of patients truly need entirely different treatment strategies
- Advanced therapies like CAR-T are being studied for the most severe cases
- Nervous system based treatments may play a future role alongside medications
- Research is increasingly focused on individualized care, not one-size-fits-all solutions
Most importantly, science is moving forward with people like you in mind.
If you have questions after watching this debrief or reading this summary, our community spaces are here for conversation and support. You are not alone, and the research world is paying attention.
Learn more about
Rheumatoid Arthritis and
The Go With Us Program
